- Supporting the development of creative seeds in academia into drug discovery through open innovation
- Fostering entry of domestic pharmaceutical companies into the vaccine business
- Contributing to meeting global health needs not only in Japan but also in emerging countries
Our Portfolio
Create Vaccine Co., Ltd.
| Outline | Development of a novel TB vaccine using human parainfluenza virus type-2 vector technology |
|---|---|
| Industry | Health/medicine |
| Commercialization stage | Early stage |
Provided Support
| Authorized Investment | Approx. ¥280 million |
|---|---|
| Announcement Date | May 22, 2014 |
| Investment Structure |
Related Press Releases
- Dec 21, 2017
- INCJ revokes decision to support Create Vaccine Co., Ltd.
- Dec 21, 2017
- Dissolution of Create Vaccine Company, Ltd.
- May 22, 2014
- Joint Investment into Create Vaccine Company, Ltd.